We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

6,600
Open access books available

177,000
International authors and editors

195M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Innovations in Down Syndrome Screening

Wendy Koster1,2, Annemieke de Vries1, Gerard Visser2 and Peter Schielen1

1National Institute for Public Health and the Environment
2Department of Obstetrics, University Medical Centre Utrecht
The Netherlands

1. Introduction

Down syndrome (DS) is the most common chromosomal abnormality, with an incidence of approximately 1 per 500 to 800 live births (Egan et al., 2004). DS is associated with an impairment of cognitive ability and physical growth, and a particular set of facial characteristics. Moreover, about 50% of all people with DS suffer from a congenital heart defect and DS patients are more prone to develop serious illnesses such as Alzheimer’s disease, leukaemia and epilepsy. These factors all contribute to a shorter life expectancy.

For decades, people developed methods to prenatally diagnose DS. In this chapter an overview is given of non-invasive screening methods for DS. The research described in this chapter was performed at the Dutch National Institute for Public Health and the Environment (RIVM). The RIVM acts as the reference laboratory for DS screening in the Netherlands and processes over 10,000 first-trimester combined tests per year. The RIVM therefore possesses an extensive collection of sera of pregnant women carrying a foetus with DS and other congenital abnormalities. For our scientific studies, serum samples from this large database were used. The aim of our research was to identify new biochemical screening markers using proteomics techniques to improve the performance of the current DS screening.

2. Down syndrome screening

2.1 A historical perspective of Down syndrome

An accurate phenotypic description of Down syndrome (DS) was published by John Langdon Down in 1866 (Down, 1866). Following descriptions of Esquirol and Séguin (Esquirol, 1838, Séguin, 1846), who wrote about phenotypic differences between mentally retarded humans, Down was the first to make the distinction between the phenotype which is now called DS and other disorders. He made this distinction based on an ethnic classification in which he discerned four types; the Ethiopian type, the Malay type, the American type and the Mongolian type (Down, 1866). Down noticed that the ‘mongolism’ occurred in more that 10% of all mentally retarded children and that it was always congenital.

At the end of the 19th century, the principle of inheritance was explained by the discovery of chromosomes in living organisms. In 1909, Morgan and colleagues began to study the
chromosomes of *Drosophila* (fruit flies), which were very suitable for genetic studies because they bred quickly and only have four chromosomes. During their experiments it was, among others, discovered that occasionally *Drosophila* possessed three sex chromosomes instead of two showing a pattern of XXY or XYY, an abnormality which they called ‘trisomy’ (Morgan et al., 1925, Morgan et al., 1915). Since this trisomy occurred when two copies of a chromosome failed to disjoin properly, it was described as non-disjunction.

Somewhat later, in the 1930s, two researchers independently linked non-disjunction to DS. Waardenburg stated that, due to the extended clinical features of humans with DS, the syndrome might very well be caused by something as complicated as a chromosomal disorder (Waardenburg, 1932). Bleyer proposed that DS occurs with fertilization or has already occurred before, during the period of maturation of the ovum or spermatozoon (Bleyer, 1934). Therefore, he thought that a chromosomal abnormality such as non-disjunction was most likely to cause DS.

Finally, in 1959, a few years after it had been established that human tissues normally contain 46 chromosomes, Lejeune and Jacobs independently discovered the presence of an extra chromosome in children with DS (Jacobs et al., 1959, Lejeune et al., 1959). Lejeune suggested, principally based on the *Drosophila* research, that the presence of an extra chromosome could well be explained in terms of non-disjunction. As individual chromosomes were identified, it appeared that the extra chromosome in DS was always the 21st chromosome. Therefore, DS was since then referred to as trisomy 21.

### 2.2 Prenatal screening for Down syndrome

The discovery of a trisomy of chromosome 21 as the underlying cause for DS and the possibility to perform a chromosome analysis on amniotic fluid allowed for the prenatal diagnosis of DS (Valenti et al., 1968).

In 1966 the first chromosome analysis of amniotic fluid was performed (Steele and Breg, 1966). This development allowed for the prenatal detection of DS, which was first achieved in 1968 (Valenti et al., 1968). The relationship between the risk of having a child with DS and advanced maternal age had been known for a long time (Penrose, 1933, Shuttleworth, 1909). A statistical estimation of this relationship is shown in figure 1. Because of an increased risk of DS, in many countries women above a certain age (usually above 35-38 years) were offered prenatal diagnosis by means of amniocentesis.

In 1972 it was discovered that very high levels of alpha fetoprotein (AFP) were present in the amniotic fluid of women carrying a child with a neural tube defect (NTD) (Brock and Sutcliffe, 1972). Two years later the association between high AFP levels and NTD was also seen in second trimester maternal serum samples (Brock et al., 1974, Wald et al., 1974), allowing for a non-invasive screening method for NTD (Wald et al., 1977). Again a few years later, in 1984, it was found that, in contrast to the elevated AFP levels in NTD pregnancies, decreased maternal serum levels of AFP in the second trimester of pregnancy could be linked to DS (Cuckle et al., 1984, Merkatz et al., 1984). This meant that prenatal screening for NTD could be extended with the screening for DS. This way, women of advanced maternal age could now be offered a screening test before opting for an invasive amniocentesis that bears a certain risk of miscarriage (Eddleman et al., 2006, Odibo et al., 2008).

The discovery of AFP as a second trimester screening marker for DS triggered researchers to look for other potential screening markers to even further improve the prenatal detection by screening. In 1987, two new screening markers were presented. Maternal serum levels of
human chorion gonadotropin (hCG) were shown to be, on average, higher in DS pregnancies (Bogart et al., 1987) while levels of unconjugated estriol (uE₃) were mostly decreased in DS (Canick et al., 1988). A year later, Wald and colleagues reported on a new method of screening using the three biochemical markers (AFP, hCG and uE₃) together with maternal age as parameters in a single test (Wald et al., 1988). This test became known as the ‘triple test’. With the triple test 60% of all DS cases could be prenatally detected at a 5% false positive rate (FPR) (Wald et al., 1988), which was a significant improvement compared to the detection of the previous screening method based on maternal age and AFP only (Cuckle et al., 1984). The triple test became increasingly popular as a screening test for DS and started to be carried out routinely in several countries. The most optimal cut-off risk for the screening was calculated to be 1 in 250 (Baumgarten, 1985). During the early 1990s, the triple test was adjusted by the replacement of hCG with the free beta subunit of hCG (fβ-hCG) (Macri et al., 1990, Ryall et al., 1992). Moreover, in 1996, inhibin-A was found to contribute to the current triple test (Wald et al., 1996) and with the addition of inhibin-A the ‘quadruple test’ was conceived.

Fig. 1. The relationship between maternal age and the risk of having a child with Down syndrome based on data from Cuckle et al. (Cuckle et al., 1987).

In the meantime the focus of prenatal screening for DS shifted more towards the first trimester of pregnancy. This development was in part due to the applicability of chorionic villus sampling, a technique that allows for karyotyping already in the first trimester. Thus, it became possible to detect DS earlier in pregnancy, what subsequently allowed for earlier termination of pregnancy. On the other hand, first trimester screening would not include screening for NTD. However, advanced ultrasound techniques were developed promising high detection rates for NTD in the second trimester. Except for fβ-hCG (Spencer et al., 1992), the parameters in the current triple test did not perform well in the distinction between DS and euploid pregnancies in the first trimester.
So, to come up with a proper test, new first trimester screening markers were necessary. In 1991, it was found that maternal serum pregnancy associated plasma protein-A (PAPP-A) was reduced about 50% in DS pregnancies (Brambati et al., 1993). Besides PAPP-A, more potential markers were studied (e.g. SPI (Kornman et al., 1998) and CA125 (Van Lith et al., 1993)), but none of those turned out to be worth adding to the screening test. The search for DS screening markers was not limited to biochemical markers; an enlarged nuchal translucency (NT) on a first trimester ultrasound scan also turned out to be predictive for DS (Nicolaides et al., 1992, Pandya et al., 1994). Combining these three screening markers (β-hCG, PAPP-A and NT) with maternal age, using a risk calculation method similar to that of the triple test, originated the ‘first trimester combined test’ (Wald and Hackshaw, 1997). Over the years, numerous studies have been published showing that with the first trimester combined test approximately 85-90% of all DS cases could be detected at a 5% FPR (Jaques et al., 2007, Nicolaides et al., 2005, Spencer and Nicolaides, 2003, Valinen et al., 2007, Wojdemann et al., 2005).

Under strict guidelines issued by the Dutch Centre for Population Research the first-trimester screening policy for DS was fully implemented in the Netherlands as of January 1, 2007. Since then, all pregnant women are offered such prenatal screening for DS, but the uptake of the test is only 23% (Schielen et al., 2008), which is rather low as compared to other countries. The detection rate (DR) of DS screening in the Netherlands is currently 76% (Wortelboer et al., 2009a).

3. Proteomics techniques to identify new screening markers for Down syndrome

The development of methods for DS screening has so far mainly been based on coincidences. The screening really is a spin-off of the neural tube defect (NTD) screening, and the most effective markers were discovered by fishing expeditions, not by thorough analysis of the causal relationship of genes on chromosome 21 and foetal or placental proteins that are likely to cause an excess or shortage in maternal serum as a result. A proteome is the entire complement of proteins including the modifications made to a particular set of proteins, produced by an organism or system. Proteomics is the field of research that aims at examination of the proteome in a certain tissue, cell type or body fluid at a certain time point. A plethora of emerging methodological tools allows for the study of proteins, e.g. their quantity, cellular location and post-translational modifications. Understanding the proteome, the structure and function of each protein, and the complexities of protein-interactions during a DS pregnancy may help in the search for additional biomarkers for current first-trimester DS screening.

Our proteomics research consists of three phases (figure 2): i) the discovery of new biomarkers for first-trimester DS screening, ii) the feasibility and validation of proteomics techniques to analyze multiple markers simultaneously, iii) the implementation of a cost-effective assay for large-scale screening programmes.

The presence of an extra chromosome in DS not only leads to anomalies of the foetus, but also of the placenta. In human trophoblast cells, the excess of oxygen radicals produced during oxygen metabolism are eliminated by natural antioxidants and superoxide dismutase (SOD). The gene responsible for this reaction is Zn-SOD and is encoded by chromosome 21. SOD expression and protein levels and activity are significantly higher (about 50%) in trophoblast cells from DS placentas (Pidoux et al., 2004). Over-expression of
Innovations in Down Syndrome Screening

Discovery

- Literature review
- Data mining

Validation & Feasibility

- Bead-based assays
- Antibody Arrays

Implementation

- Fingerprick
- Combining diseases

Fig. 2. Three phases of proteomics research for DS screening described in this chapter.

SOD hampers normal trophoblast formation; DS trophoblast cells cannot fully compensate for the reduced oxidative stress resulting in placental abnormalities. DS placenta show signs of impaired differentiation, aggregation and fusion of their trophoblast cells. This could lead to undervascularisation, hypotrophy and cell apoptosis of the placenta already in the first trimester of pregnancy (Koster et al., 2010a). As a result of these pathological changes deregulation and/or differential expression occurs for proteins, e.g. cytokines and growth factors, involved in implantation and placental development (Bromage et al., 2000, Vesce et al., 2002). This may cause an increased or decreased placental expression of biological markers (hormones and proteins). PAPP-A and \( \beta \)-hCG, currently used as DS screening markers in the first-trimester combined test, are such markers. PAPP-A is a protein which is thought to be an important regulator of IGF bioavailability and cell growth (Giudice et al., 2002) and \( \beta \)-hCG is a subunit of total hCG, which is the most important hormone involved in early pregnancy and provides for the maintenance of the corpus luteum and of pregnancy (Stenman et al., 2006). Based on this knowledge the differential expression of other placenta derived proteins, given that it is traceable in maternal blood, could be used in the search for new screening markers.

In the discovery phase of our research, an extensive review of the literature was carried out to study normal placental development and function during early pregnancy (Koster et al., 2010a). Using this knowledge, candidate biomarkers were proposed which may be useful in screening for DS. Current screening markers for DS indeed mainly originate from the placenta, but can also be traced to the foetal liver, e.g. alpha-fetoprotein (AFP). It is therefore hypothesized that new screening markers may also originate from these tissues. However, a prerequisite of a good screening marker is that concentrations of a protein are detectable in maternal serum. The amount of information on genes and proteins in public databases is increasing rapidly, which allows for a bioinformatics approach that involves automated collection and combination of information from biological databases, known as data mining. A bioinformatics approach was developed to use data from the literature on genes and...
protein expression and data-textmining tools. This way, a list of 49 potential DS screening markers was generated (Pennings et al., 2009). The list included three biomarkers that are already used for DS screening (AFP, $\beta$-hCG and PAPP-A) and several others, among which proteins that have been examined as potential biomarkers before. Furthermore, there was a large overlap between the proposed screening markers based on the literature review and the data mining (table 1).

Biomarker discovery research within our proteomics project also included the use of mouse-models for biomarker identification (Pennings et al, 2011). Breeding healthy female mice and male transgenic mice with DS (type Ts(16C-tel)1Cje; The Jackson Laboratory, Bar Harbor, ME, USA) produces healthy females pregnant with, on average, 50% DS embryos. Blood was drawn from the pregnant mice during the first trimester, for the identification of potential screening markers in maternal serum. Then, the pregnancy was terminated and the placenta and foetal organs were collected. Gene profiles were analyzed using a whole genome microarray approach to study the difference between DS and unaffected siblings. Genes that showed over- or underexpression in the placentas of DS foetuses were C2cd2, Dyrk1a, Ifnar2, Morc3, Sfrs15, Sod1, Tmprss2, Fgfbp3. Ongoing research focuses on the serum detectability of these gene products, and their potential as a biomarker for DS screening in human serum.

We continued our search for potential screening markers by examining the proteins that have been suggested as first-trimester screening markers for aneuploidies in international studies. One of those markers is placental protein 13 (PP13) which plays an important role in the implantation and modelling of foetal-maternal blood spaces between placenta and endometrium. PP13 is produced by the placenta, which is hampered in trisomic pregnancies, and was found to be decreased in DS pregnancies and, to greater extent, in trisomy 18 and 13 pregnancies (Akolekar et al., 2010, Koster et al., 2009b). Serum concentrations of a disintegrin and metalloprotease 12 (ADAM12) and placental growth factor (PIGF) are also decreased in DS pregnancies (Wortelboer et al., 2009b, Zaragoza et al., 2009). Total hCG (thCG), which is a screening marker for DS in the second trimester of pregnancy, is increased in maternal serum from first-trimester DS pregnancies (Hallahan et al., 2000). However, when these four markers were added to the current first-trimester combined test algorithm the DR increased by only 3% (table 2a) (Koster et al., 2010d).

These studies show that the predictive power of maternal serum markers is not constant during the first trimester. For three markers (PAPP-A, ADAM12 and PP13) the difference between DS and unaffected pregnancies is more distinct early in the first trimester (before 11 weeks), while for the remaining markers (ff$\beta$-hCG, thCG and PIGF) the difference is more pronounced later on (after 11 weeks) (Kuc et al., 2010). Based on this knowledge, it would be useful to draw two separate blood samples (a so-called two-sample combined test) to increase the DR of first-trimester screening to almost 90% at a 5% FPR, which is obviously a tremendous improvement compared to the DR of the current screening program (table 2b).

On the other hand, adding new markers to the screening test and taking an extra blood sample bears extra costs and complicates the logistic process of first-trimester screening. A cost-effectiveness analysis is therefore necessary to evaluate the potential of such a two-sample first-trimester screening setting.

A more experimental proteomics approach was carried out by analyzing 90 different proteins from a pre-existing non-pregnancy-specific bead-based multiplexed immunoassay. By comparing the protein concentrations in a small cohort of DS and control sera, seven
<table>
<thead>
<tr>
<th>Marker Description</th>
<th>Function</th>
<th>Potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAM12 ADAM metallopeptidase domain 12</td>
<td>* Involved in proteolysis, adhesion, fusion and intracellular signaling * Interacts with IGF binding proteins</td>
<td>biomarker</td>
</tr>
<tr>
<td>EGF Epidermal growth factor (β-urogastrone)</td>
<td>* Promotes differentiation and prevents apoptosis in trophoblasts * Involved in trophoblast invasion and proliferation</td>
<td>examined</td>
</tr>
<tr>
<td>hCG Human chorionic gonadotropin</td>
<td>* Glycoprotein hormone that consists of a common α subunit and a unique β subunit * Stimulates the ovaries to synthesize steroids to maintain pregnancy * Involved in trophoblast differentiation and cell aggregation</td>
<td>examined</td>
</tr>
<tr>
<td>IGF-1 Insulin-like growth factor 1</td>
<td>* Regulates placental growth and transport, trophoblast invasion and placental angiogenesis</td>
<td>examined</td>
</tr>
<tr>
<td>IGF-2 Insulin-like growth factor 2</td>
<td>* Has large effects on cell proliferation and differentiation</td>
<td>examined</td>
</tr>
<tr>
<td>IGFBP-1 Insulin-like growth factor binding protein 1</td>
<td>* Binds both IGF-I and II</td>
<td>examined</td>
</tr>
<tr>
<td>IGFBP-2 Insulin-like growth factor binding protein 2</td>
<td>* Restricts trophoblast invasion</td>
<td>examined</td>
</tr>
<tr>
<td>IGFBP-3 Insulin-like growth factor binding protein 3</td>
<td>* Stimulates trophoblast cell migration and invasion</td>
<td>examined</td>
</tr>
<tr>
<td>IGFBP-4 Insulin-like growth factor binding protein 4</td>
<td>* Regulate IGF bioavailability and cell growth</td>
<td>unknown</td>
</tr>
<tr>
<td>IGFBP-5 Insulin-like growth factor binding protein 5</td>
<td>unknown</td>
<td>unknown</td>
</tr>
<tr>
<td>IGFBP-7 Insulin-like growth factor binding protein 7</td>
<td>unknown</td>
<td>unknown</td>
</tr>
<tr>
<td>IL-1β Interleukin 1β</td>
<td>* Involved in angiogenesis, growth and immunomodulation * Regulation of fetal and uterine metabolism</td>
<td>examined</td>
</tr>
<tr>
<td>MMP-2 Matrix metallopeptidase 2 (gelatinase A)</td>
<td>* Involved in extracellular matrix degradation in embryonic development, reproduction and tissue remodeling * Play a role in endometrial menstrual breakdown, regulation of vascularization and the inflammatory response</td>
<td>unknown</td>
</tr>
<tr>
<td>MMP-9 Matrix metallopeptidase 9 (gelatinase B)</td>
<td>* Regulate several growth factors and cytokines</td>
<td>unknown</td>
</tr>
<tr>
<td>PLAP Pregnancy-associated plasma protein A</td>
<td>* Cleaves IGFBPs * Important regulator of IGF bioavailability and cell growth</td>
<td>In use</td>
</tr>
<tr>
<td>PGH Placenta-specific growth hormone</td>
<td>* Member of the somatotropin/prolactin family that is expressed mainly in the placenta * Plays an important role in growth control. * Has a key role in the control of IGF-1 levels</td>
<td>biomarker</td>
</tr>
<tr>
<td>PLGF Placental growth factor</td>
<td>* Mainly involved in angiogenesis * Has an autocrine function in regulating trophoblast function</td>
<td>unknown</td>
</tr>
<tr>
<td>SOD-1 Superoxide dismutase 1</td>
<td>* Binds copper and zinc ions * Responsible for catalyzing free superoxide radicals</td>
<td>examined</td>
</tr>
<tr>
<td>TGF-β Transforming growth factor β 1</td>
<td>* Inhibits cytotrophoblast migration * Decreases trophoblast proliferation * Increases formation of placental giant cells * Regulates many other growth factors</td>
<td>unknown</td>
</tr>
<tr>
<td>TIMP-1 Tissue inhibitor of matrix metallopeptidase 1</td>
<td>* Natural inhibitors of MMPs * Promote cell proliferation * Anti-apoptotic function * Suppress endothelial proliferation * Regulates many other growth factors</td>
<td>unknown</td>
</tr>
<tr>
<td>TIMP-2 Tissue inhibitor of matrix metallopeptidase 2</td>
<td>* Maintain tissue homeostasis</td>
<td>unknown</td>
</tr>
<tr>
<td>TIMP-3 Tissue inhibitor of matrix metallopeptidase 3</td>
<td>* Regulate platelet aggregation and recruitment</td>
<td>unknown</td>
</tr>
<tr>
<td>TIMP-4 Tissue inhibitor of matrix metallopeptidase 4</td>
<td>* Play a role in hormonal regulation and endometrial tissue remodeling</td>
<td>unknown</td>
</tr>
<tr>
<td>VEGF Vascular endothelial growth factor</td>
<td>* Mediates vascular permeability * Inhibits angiogenesis, vasocagation and endothelial cell proliferation</td>
<td>examined</td>
</tr>
</tbody>
</table>

Table 1. Early biomarkers involved in placental development according to a literature study and data-mining. Potential for DS screening is indicated as follows: In use, currently widely used in DS screening; Biomarker, studies showed overall significant concentrations; Examined, examined as biomarker but not significant or inconclusive overall results.
potential screening markers were identified (Koster et al., 2009a): alpha fetoprotein (AFP), epidermal growth factor (EGF), extracellular rage binding protein (EN-RAGE), eotaxin, haptoglobin (HP), insulin (INS) and lipoprotein A (LPA). None of the identified proteins is linked to genes located on chromosome 21. However, some of the markers are known to be highly expressed in the placenta or foetal liver and were also proposed in the candidate biomarker lists from the previously described discovery studies. Unfortunately, none of the seven identified single markers showed significant differences between cases and controls. It might be that biomarkers with large distinctive power were not present on the immunoassay or, alternatively, that fold changes are inherently not high in maternal blood. Interestingly, the addition of the whole panel of seven biomarkers to the current screening test provided a significant improvement of the detection rate for DS.

Despite these promising results, it is obvious that test performance is always better when a screening test is applied to the same cases from which the markers are derived and therefore application of the proposed markers on a different cohort of cases is essential to establish the

<table>
<thead>
<tr>
<th>A</th>
<th>One-sample test</th>
<th>DR at FPR (8-13 wks)</th>
<th>5%</th>
<th>3%</th>
<th>1%</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAPP-A &amp; fβ-hCG</td>
<td>77 71 59</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ADAM12</td>
<td>77 72 60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ thCG</td>
<td>77 71 60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ PP13</td>
<td>77 71 60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ PIGF</td>
<td>78 73 61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ADAM12, thCG, PP13 &amp; PIGF</td>
<td>80 74 63</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ADAM12, thCG &amp; PIGF</td>
<td>79 74 62</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ADAM12 &amp; PIGF</td>
<td>79 73 62</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B</th>
<th>Two-sample test</th>
<th>DR at FPR 1st (8-10 wks)</th>
<th>2nd (11-13 wks)</th>
<th>5%</th>
<th>3%</th>
<th>1%</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAPP-A</td>
<td>fβ-hCG</td>
<td>83 79 68</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ADAM12</td>
<td>84 80 69</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ thCG</td>
<td>85 80 70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ PP13</td>
<td>84 79 69</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ PIGF</td>
<td>85 80 69</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ADAM12 &amp; PP13</td>
<td>+ thCG &amp; PIGF</td>
<td>89 85 75</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ADAM12</td>
<td>+ thCG &amp; PLGF</td>
<td>88 84 74</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ADAM12</td>
<td>+ PIGF</td>
<td>85 81 70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Modeled detection rates (DR) at given false positive rates (FPR) for NT at 11-13 weeks and several serum marker combinations in a one-sample (A) or two-sample test (B). Models containing all markers are displayed in bold.
Fig. 2. Boxplots showing the distinction between Down syndrome cases (grey) and the controls (white) by plotting the median, quartiles and minimum/maximum values. (A) Difference between cases and controls when the three current screening markers (PAPP-A, ß-hCG and NT) are used, (B) Difference between cases and controls when the current three screening markers are combined with the seven newly identified potential biomarkers (AFP, EGF, EN-RAGE, Eotaxin, HP, INS and LPA). Values along the vertical axis indicate prediction scores expressed as arbitrary units.

true diagnostic accuracy of the immunoassay. This was done in a subsequent validation study in which 34 DS cases and matching controls were included to confirm the predictive value of the seven markers found in the discovery study. EGF and EN-RAGE were confirmed to be potential screening markers for DS and improved the DR of the current first-trimester combined test with approximately 6% (table 3) (Koster et al., 2010b). This may seem rather disappointing considering the initial identification of seven potential markers. On the other hand, the finding that two markers again improved the DS screening performance in an independent study is highly encouraging. Clearly, large scale validation experiments need to be performed to provide sufficient evidence for potential markers before they can be implemented in a screening test.

4. Screening for Down syndrome using cell-free foetal DNA/RNA in maternal blood

Currently, not only knowledge to do in-depth evaluations based on proteomic techniques is available, but more and more research focuses on the genomic detection of DS in maternal
Table 3. Modeled detection rates (DR) at a given 5% false positive rate (FPR) for several marker combinations. Models were fitted based on the data of the discovery study or based on the validation study and tested on both datasets. DRs displayed in bold indicate an improvement compared to the current screening model.

<table>
<thead>
<tr>
<th>Markers in the model</th>
<th>Discovery fit + (\text{discovery data})</th>
<th>Discovery fit + (\text{validation data})</th>
<th>Validation fit + (\text{discovery data})</th>
<th>Validation fit + (\text{validation data})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current screening (PAPP-A, (\beta)-hCG, NT)</td>
<td>56.2</td>
<td>65.2</td>
<td>39.7</td>
<td>64.0</td>
</tr>
<tr>
<td>PAPP-A + (\beta)-hCG</td>
<td>38.9</td>
<td>57.1</td>
<td>32.7</td>
<td>57.6</td>
</tr>
<tr>
<td>Current + AFP</td>
<td>58.9</td>
<td>64.1</td>
<td>40.6</td>
<td>64.0</td>
</tr>
<tr>
<td>Current + EGF</td>
<td>62.6</td>
<td>67.1</td>
<td>51.7</td>
<td>68.0</td>
</tr>
<tr>
<td>Current + EN-RAGE</td>
<td>58.7</td>
<td>68.4</td>
<td>47.7</td>
<td>68.1</td>
</tr>
<tr>
<td>Current + Eotaxin</td>
<td>61.1</td>
<td>55.8</td>
<td>40.7</td>
<td>63.8</td>
</tr>
<tr>
<td>Current + Haptoglobin</td>
<td>61.8</td>
<td>62.3</td>
<td>36.1</td>
<td>64.2</td>
</tr>
<tr>
<td>Current + Insulin</td>
<td>59.7</td>
<td>65.2</td>
<td>37.4</td>
<td>63.7</td>
</tr>
<tr>
<td>Current + LPA</td>
<td>61.0</td>
<td>65.0</td>
<td>51.6</td>
<td>63.4</td>
</tr>
<tr>
<td>10 markers (current + 7 new)</td>
<td>82.5</td>
<td>52.4</td>
<td>59.2</td>
<td>71.5</td>
</tr>
<tr>
<td>Current + EGF + EN-RAGE</td>
<td>62.1</td>
<td>70.1</td>
<td>53.8</td>
<td>71.4</td>
</tr>
</tbody>
</table>

Prenatal Diagnosis and Screening for Down Syndrome

Markers in the model

Blood. We feel therefore that we should devote a paragraph on the potential value of this technique and its possible role within the screening process. One line of research concerning DS screening tries to put high-end sequencing quantification techniques for DNA and RNA into use to quantify foetal DNA or RNA, either in nuclei of foetal cells or free-floating in maternal serum (Lo, 2000). Non-invasive foetal genotyping became feasible when, foetal DNA was found to constitute approximately 10% of the DNA circulating in the mother’s plasma (Lo et al., 1998). However, determination of the maternally inherited alleles was a considerable challenge because the foetal contribution to the plasma DNA can only result in subtle shifts to the total allelic balance, rather than providing a novel allele. Currently, the most promising technique is so-called massive parallel genomic sequencing. This technique can identify and quantify many DNA fragments in a relatively short time span (Chiu et al., 2008, Fan et al., 2008). Recently, a large-scale study in a high risk cohort was conducted to investigate the performance of massive parallel genomic sequencing in terms of detection and false positive rates. In this study, all DS pregnancies could be identified at a 2.1% false positive rate (Chiu et al., 2011). The authors claim that if such a test would be carried out in all women who initially had a high risk pregnancy (based on first trimester screening), only very few women would need a referral for an invasive diagnostic procedure such as amniocentesis. However, it is unclear how the test would perform in a more representative low-risk pregnant population.

With this promising non-invasive technique, it seems possible to provide definite identification of DS. However, there are still limitations to the technique and some reputable experts in the field have expressed doubts concerning these developments (Community Corner Nature Medicine, 2011). This line of research has been going on for over ten years now; the major technical challenges of sequencing foetal DNA from maternal blood may have been largely solved, but now the practical issues raised by applying this technology need to be addressed. For a diagnostic test, a false positive rate of 2.1% is unacceptable, since it would lead to termination of pregnancy in an equal percentage unaffected pregnancies. For a screening test on the other hand, the technique is still too expensive and time-
Innovations in Down Syndrome Screening

141

consuming. And furthermore, if this technique keeps evolving it might even become possible to prenatally offer whole genome sequencing, which obviously raises a complex set of social and ethical issues.

So we feel that, although it is likely that, somewhere in the near future, massive parallel genomic sequencing will be used as an intermediate step in the prenatal detection of DS to decrease the number of invasive procedures such as amniocentesis, the technique is still a long way from implementation in a high-throughput screening setting.

5. Future perspectives and ongoing research

The research described in this chapter focuses on the directive search for new markers for DS using the ever expanding knowledge of the human genome and proteome and combines both laboratory techniques and digital evaluation of data (data mining). The current first trimester combined test is based on enzyme-linked immunosorbent assay (ELISA) methods, which is widely used for quantitative protein measurements. Recently, two-dimensional gel electrophoresis (2-D), tandem mass spectrometry (MS-MS) and bead-based multiplexed immunoassays have been used to identify several potential biomarkers in amniotic fluid and maternal blood (Busch et al., 2005, Kolialexi et al., 2008, Nagalla et al., 2007, Tsangaris et al., 2006), clearly demonstrating the potential of applying proteomics techniques in the quest for new biomarkers. Bead-based multiplexed immunoassays use color-coded tiny beads in up to 100 distinct sets. Coating each bead set with a specific reagent allows the capture and detection of many specific analytes, such as proteins, from a sample. Next, labeled beads are incubated with serum samples and, subsequently, with a detection antibody labeled with a reporter dye in a bead-based immunoassay. Flow cytometry equipment measures the internal dyes to identify each particle and the reporter dye captured during the assay (Krishhan et al., 2009). Another proteomics technique is the use of Antibody microarrays (Ab-arrays). Ab-arrays are a platform for protein expression profiling. Small amounts of capture antibodies for the selected targets are immobilized or spotted on a very small area on coated glass slides. The high density of the capture antibodies in the spots that is obtained enables high sensitivity (Ekins, 1989). These technologies allow analyzing many unique markers within a single sample, both rapidly and precisely, in a high-throughput setting. In the boost of new development the question arises whether these advanced detection techniques will be available at a reasonable cost, a prerequisite for screening tests. In principle however, Ab-array techniques are calculated to cost within the range of 20-50 Euros per screening.

In recent years, the focus of prenatal screening has expanded. Several studies have been performed to evaluate the potential of prenatal screening for foetal chromosomal abnormalities other than DS, in particular Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13). With the first-trimester combined test it is possible to detect these trisomies using the same algorithm as for DS screening (Spencer et al., 2000, Tul et al., 1999). In trisomy 18 and 13 pregnancies PAPP-A levels are decreased to a greater extent than in DS and the NT is often very large. However, as opposed to DS, serum concentrations of ß-hCG are decreased in trisomy 18 and 13 pregnancies. Thus, with a slight adjustment of the DS risk calculation, it would be possible to provide separate risks specifically for trisomy 18 and 13. This would lead to the detection of many trisomy 18 and 13 cases with only 0.2% extra false positives (Koster et al., 2010c).

www.intechopen.com
This spin-off of the current proteomics project may have opened a completely new field of research. Currently, a similar approach has been set up to identify potential screening markers for pregnancy complications such as pre-eclampsia (PE), intrauterine growth restriction and foetal death. PE is a serious complication of pregnancy that affects approximately 1-2% of all pregnant women and it is the leading cause of maternal and perinatal morbidity and mortality (Gaugler-Senden et al., 2006). Because of the serious health consequences of PE, risk assessment for PE is highly recommended. Early identification of women at risk might facilitate better antenatal surveillance, timely intervention and better outcomes.

Especially new proteomic techniques will need only minute amounts of test material; 10-20 micro-litres serum instead of 1-2 ml. Hypothetically, this downscaling opens the possibility to draw small amounts of blood and to replace the relatively laborious venous puncture with a finger prick. Our first studies comparing venous blood with capillary blood (derived from a finger prick), drawn at the same time from pregnant women, indeed show that capillary blood can be reliably used to determine the currently used biomarkers in serum. The laboratory will be able to analyze a combination of approximately ten markers. Based on these developments, it must surely be possible to detect, in the same samples, all parameters of prenatal screening (e.g. irregular blood types and infectious diseases, like HIV and hepatitis) and to identify high risks for foetal (e.g. chromosomal abnormalities) and maternal (e.g. pre-eclampsia) pregnancy complications.

In the next coming years, the outline of such a future prenatal screening is feasible, however; it will probably take some time before these methods can be tested in large cohorts that proof their efficacy as a screening tool, a bare necessity before actual implementation can take place.

6. Conclusion

It is anticipated that the introduction of a new screening method consists of a discovery phase, taking 1-3 years, a validation phase, taking 2-5 years, and an implementation phase, taking 5-7 years. This means that of all of the discoveries presented in this paper, which are clearly done in the realm of the discovery phase, very few will make it to becoming an element of an implemented screening test. While we cannot predict what the prenatal screening test for Down syndrome, other aneuploidies and foetal and maternal health will be in ten years time, we can state that it will not be the first trimester combined test. The past decades have learned sufficiently that the screening tests, while not being volatile, are liable to changes, and this will not stop in the next years. It is safe to say that the future test will use the complete array of proteomics, genomics and ultrasound markers, to provide a continuum of tests, with the sole purpose of improving in general the outcome of pregnancies, including the health perspective of the mother, worldwide.

7. Acknowledgments

This chapter is based on research described in PhD-thesis “Innovations in Down syndrome screening” by M.P.H. Koster, Utrecht University, the Netherlands; 2010. ISBN: 978-90-5335-305-9 [dissertation]. The authors would like to thank everyone who contributed to this research: Idder Belmouden, Bert Elvers, José Ferreira, Gert-Jan Gödeke, Kirsten Heetkamp, Sandra Imholz, Mark Jonker, Gerard Loeber, Jeroen Pennings, Johan Reimerink, Wendy
Rodenburg and Conny van Oostrom at the National Institute for Public Health and the Environment; Sylwia Kuc, Philip Stoutenbeek and Esther Wortelboer at the Department of Obstetrics of the University Medical Centre Utrecht; Howard Cuckle at Columbia University, New York, USA.

8. References


Community Corner: Opening the Pandora’s box of prenatal genetic testing. *Nat Med*, 17, 250-1.


www.intechopen.com


This book provides a concise yet comprehensive source of current information on Down syndrome. Research workers, scientists, medical graduates and paediatricians will find it an excellent source for reference and review. This book focuses on exciting areas of research on prenatal diagnosis - Down syndrome screening after assisted reproduction techniques, noninvasive techniques, genetic counselling and ethical issues. Whilst aimed primarily at research worker on Down syndrome, we hope that the appeal of this book will extend beyond the narrow confines of academic interest and be of interest to a wider audience, especially parents and relatives of Down syndrome patients.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
